Clinical Trials
16 trialsNCT00897702 2026-01-28
Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer
Memorial Sloan Kettering Cancer Center
Completed
NCT00436254 2025-04-06
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Phase 1 Completed
NCT00499083 2023-09-29
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Phase 2 Completed
NCT00470574 2020-11-18
Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00892515 2020-04-16
Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase NA Completed
NCT00640861 2018-10-31
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00847171 2018-09-26
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00821964 2018-01-02
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
University of Washington
Phase 2 Completed
NCT00899197 2017-08-01
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Wake Forest University Health Sciences
Terminated
NCT00900068 2017-05-09
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
OHSU Knight Cancer Institute
Terminated
NCT00896857 2017-03-15
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer
Wake Forest University Health Sciences
Completed
NCT00900133 2015-10-02
Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer
Case Comprehensive Cancer Center
Completed
NCT00228358 2014-11-11
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
University of Washington
Phase 1 Completed
NCT01219907 2013-05-17
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
University of Washington
Phase 1 Withdrawn
NCT00898703 2012-12-17
Studying Blood Samples in Women With Breast Cancer or a History of Breast Cancer
University of Arizona
Completed
NCT00361049 2010-11-05
Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant
Case Comprehensive Cancer Center
Phase 1 Completed